Business Description
Atara Biotherapeutics Inc
NAICS : 325412
SIC : 2836
Compare
Compare
Traded in other countries / regions
AT2.Germany
•
0HIY.UK
•
ATRA.USA
Description
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and CAR T Programs.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.18 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.25 | |||||
| Debt-to-EBITDA | -0.22 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -4.56 | |||||
| Beneish M-Score | 5.96 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 12.8 | |||||
| 3-Year EPS without NRI Growth Rate | 11.7 | |||||
| 3-Year FCF Growth Rate | 20.6 | |||||
| 3-Year Book Growth Rate | -25.5 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.43 | |||||
| 9-Day RSI | 57.81 | |||||
| 14-Day RSI | 52.83 | |||||
| 6-1 Month Momentum % | -55.05 | |||||
| 12-1 Month Momentum % | -75.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.28 | |||||
| Quick Ratio | 5.28 | |||||
| Cash Ratio | 5.04 | |||||
| Days Sales Outstanding | 3.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -25.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -415.77 | |||||
| Net Margin % | -344.87 | |||||
| ROE % | -88.25 | |||||
| ROA % | -56.07 | |||||
| ROIC % | -211.54 | |||||
| ROC (Joel Greenblatt) % | -450.97 | |||||
| ROCE % | -84.81 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.95 | |||||
| PB Ratio | 1.56 | |||||
| Price-to-Tangible-Book | 1.53 | |||||
| EV-to-EBIT | -0.43 | |||||
| EV-to-EBITDA | -0.44 | |||||
| EV-to-Revenue | 1.86 | |||||
| EV-to-Forward-Revenue | 1.11 | |||||
| EV-to-FCF | -0.48 | |||||
| Price-to-Net-Current-Asset-Value | 2.35 | |||||
| Price-to-Net-Cash | 2.58 | |||||
| Earnings Yield (Greenblatt) % | -226.47 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ATRA
Peter Lynch Chart
Performance
Dividend
Annualized Return %
Total Annual Return %
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 71.811 | ||
| EPS (TTM) ($) | -2.55 | ||
| Beta | 0.36 | ||
| Volatility % | 102.02 | ||
| 14-Day RSI | 52.83 | ||
| 14-Day ATR ($) | 0.3408 | ||
| 20-Day SMA ($) | 3.9995 | ||
| 12-1 Month Momentum % | -75.7 | ||
| 52-Week Range ($) | 2.83 - 20.04 | ||
| Shares Outstanding (Mil) | 94.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Atara Biotherapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Atara Biotherapeutics Inc Analysis
Share your researchHeadlines
See More
No news.